Literature DB >> 3052634

Factors that accelerate or retard red blood cell senescence.

S A Landaw1.   

Abstract

This article explores information concerning alterations in the time of age-related red blood cell (rbc) death (rbc senescence) in experimental animals and humans. Those factors that accelerate or retard the mean time for senescent death [the mean potential rbc life-span, (T)] are discussed; specifically excluded are conditions in which rbc survival is shortened due to an increase in the rate of age-independent [random hemolysis, (k)]rbc death. The factors prolonging senescence are reduction in metabolic rate through hibernation, reduced environmental temperature, hypophysectomy and thyroidectomy, and splenectomy. In general, these processes prolong rbc senescence by about 10%-15% in the models studied to date. The failure of splenectomy to prolong rbc senescence to any physiologically meaningful extent casts serious doubt on the concept that splenic processes are a major factor in the senescence process. Rbcs made under conditions of increased erythropoiesis and/or increased metabolic rate show acceleration of senescence. Thus, rbcs of animals treated with thyroxine show a 15% acceleration of senescence. "Stress reticulocytes" and normal full-term human newborn rbc may show up to 25% reduction in (T). The maximum acceleration seen to date is 50%-90%, as seen in the rbcs of the fetal and newborn rat. rbc senescence is not accelerated in rats with splenomegaly and increased rates of random hemolysis, again casting strong doubts on the spleen's ability to alter rbc senescence by progressively modifying the rbc during successive passages through that organ. It is postulated that rbc senescence is mainly a function of the red cell's initial endowment, particularly in the dynamic ability of that cell (and its membrane) to adapt to cumulative stresses that exist during its circulation through the body.

Entities:  

Mesh:

Year:  1988        PMID: 3052634

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  22 in total

1.  Should erythrocyte destruction in vivo be through phagocytosis alone?

Authors:  R K Saxena
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

2.  Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Authors:  Nageshwar R Budha; Andreas Kovar; Bernd Meibohm
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

3.  Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys.

Authors:  Wojciech Krzyzanski; Jim J Xiao; Barbra Sasu; Beth Hinkle; Juan Jose Perez-Ruixo
Journal:  AAPS J       Date:  2016-02-25       Impact factor: 4.009

4.  The role of band 3 protein in oxygen delivery by red blood cells.

Authors:  N Hamasaki
Journal:  Indian J Clin Biochem       Date:  1999-01

5.  Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.

Authors:  Donald E Moss; Ruth G Perez; Haruo Kobayashi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  Exercise, training and red blood cell turnover.

Authors:  J A Smith
Journal:  Sports Med       Date:  1995-01       Impact factor: 11.136

7.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

8.  A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Peter Veng-Pedersen
Journal:  Transfusion       Date:  2012-10-04       Impact factor: 3.157

9.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

Review 10.  Red Blood Cell Dysfunction in Critical Illness.

Authors:  Stephen Rogers; Allan Doctor
Journal:  Crit Care Clin       Date:  2020-02-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.